dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Dimitrova, Dimana |
dc.contributor.author | Nademi, Zohreh |
dc.contributor.author | Maccari, Maria Elena |
dc.contributor.author | Ehl, Stephan |
dc.contributor.author | Uzel, Gulbu |
dc.contributor.author | Tomoda, Takahiro |
dc.contributor.author | García Prat, Marina |
dc.contributor.author | Soler Palacín, Pere |
dc.date.accessioned | 2022-03-11T14:02:16Z |
dc.date.available | 2022-03-11T14:02:16Z |
dc.date.copyright | 2021 |
dc.date.issued | 2022-01 |
dc.identifier.citation | Dimitrova D, Nademi Z, Maccari ME, Ehl S, Uzel G, Tomoda T, et al. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. J Allergy Clin Immunol. 2022 Jan;149(1):410-421.e7. |
dc.identifier.issn | 0091-6749 |
dc.identifier.uri | https://hdl.handle.net/11351/7151 |
dc.description | Immunodeficiència primària; Limfoproliferació; Inhibidor de mTOR |
dc.description.sponsorship | This research was funded in part from the Intramural Program of the National Cancer Institute, National Institutes of Health. The funding source had no involvement in study design; collection, analysis, and interpretation of data; writing of the report; or in the decision to submit the article for publication. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Journal of Allergy and Clinical Immunology;149(1) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Síndromes de deficiència immunitària - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Cèl·lules mare hematopoètiques - Trasplantació |
dc.subject.mesh | Hematopoietic Stem Cell Transplantation |
dc.subject.mesh | Immunologic Deficiency Syndromes |
dc.subject.mesh | /therapy |
dc.subject.mesh | Treatment Outcome |
dc.title | International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.jaci.2021.04.036 |
dc.subject.decs | trasplante de células madre hematopoyéticas |
dc.subject.decs | síndromes de inmunodeficiencia |
dc.subject.decs | /terapia |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1016/j.jaci.2021.04.036 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Dimitrova D] Experimental Transplantation and Immunotherapy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md. [Nademi Z] Children’s Bone Marrow Transplant Unit, Great North Children’s Hospital, Newcastle upon Tyne, United Kingdom. The Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. [Maccari ME, Ehl S] Department of Pediatric Hematology and Oncology, Center for Pediatrics, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Center for Chronic Immunodeficiency, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. [Uzel G] Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. [Tomoda T] Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan. [Garcia-Prat M, Soler-Palacín P] Unitat de Patologia Infecciosa i Immunodeficiències de Pediatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34033842 |
dc.identifier.wos | 000747922700010 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |